SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABSW
SAB Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.60+0.07 (+2.77%)
Close on Oct 19, 2026
- Market cap
- $207.36M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Net income | – | – | -8.0% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 86.2% | 15.0% | |
| Return on assets | – | – | 12.2% | |
| Current ratio | – | 3.11 | 9.46 | |
| Debt to equity | – | 0.00 | – | |
| Net debt to EBITDA | – | -0.59× | – | |
| Interest coverage | – | 43.8× | -203.4× | |
| Capex to revenue | – | 23.0% | – | |
| Diluted shares | – | 5M | 61M |
Where the cash went
Fiscal 2021 to 2025, five years combined
SAB Biotherapeutics generated $129.63M from operations and spent $14.58M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$129.63M
Used
$14.58M
Capital expenditure$14.58M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2579.0%
×Asset turnover0.02×
×Equity multiplier1.54×
=Return on equity, FY2024-81.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -2579.0% | 0.02× | 1.54× | -81.9% |
| FY2023 | -1884.5% | 0.03× | 1.53× | -95.5% |
| FY2022 | -78.4% | 0.36× | 1.90× | -53.8% |
| FY2021 | -28.2% | 0.88× | 1.78× | -44.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$13.27M
- Cash generatingOperating cash flow above zero-$44.78M
- Return on assets improvedROA up on the prior year-40.6% → 30.0%
- Earnings backed by cashOperating cash flow above net income-$44.78M vs $13.27M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose2.98 → 9.46
- No dilutionShare count did not rise9M → 61M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.00